BioNTech and Pfizer have come out with their own vaccines in collaboration, which has shown great potential during the human trials. This has become one of four vaccines that have shown potential results in human trials. The three other companies that have displayed promising results are Moderna, CanSino Biologics, and Inovio Pharmaceuticals.
The research, which is published in the preprint server medRxiv and is yet to be peer-reviewed, describes the preliminary clinical data for the candidate vaccine — nucleoside-modified messenger RNA (modRNA), BNT162b1. The research results that were published stated that the antibodies in the patients who had been given two shots of the developed vaccine were greater than those patients who had received plasma therapy. It was also reported that of the two dosages that had been administered the one with a higher dosage was followed by a short fever after the second shot. A third higher concentration dosage was not administered for the second time following an injection pain.
BioNTech and Pfizer will now pick the most promising of four experimental vaccines for a trial involving up to 30,000 healthy participants, which is likely to begin in the United States and Europe in late July if it gets the regulatory green light. Following the release of these research results, The stock prices of Pfizer and BioNTech rose up by 4.4% and 8% respectively.
It is to be noted that no COVID-19 vaccine has so far been approved to be used for commercial purposes. As the world grapples with a staggering 10.4 million case record with 5, 14,000 deaths, vaccines are the need of the hour.